Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay
- 1 March 1995
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 33 (3) , 661-7
- https://doi.org/10.1128/jcm.33.3.661-667.1995
Abstract
We describe a simple microtiter method for determining the susceptibility of Candida albicans and hyphal forms of Aspergillus fumigatus against antifungal agents. The assay measures mitochondrial respiration by determining reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to formazan, a process that is enhanced in the presence of menadione. C. albicans or conidial suspensions of A. fumigatus are seeded into microtiter plates. Hyphal outgrowth of Aspergillus spp. was achieved by a 12 to 14-h culture at 30 degrees C. Antifungal agents (amphotericin B, fluconazole, itraconazole) were added to the cultures for 24 h. Thereafter, incubations were continued for 3 h in the presence of MTT plus 0.1 mM menadione. Formazan formation was quantified photometrically after extraction of the formazan with acid isopropanol. Well-defined dose-response curves reflecting impairment of mitochondrial function by the antifungal agents were obtained. With C. albicans, the results correlated excellently with the MIC determinations performed according to the standard macrodilution procedure. In confirmation of a recent report, it was found that fluconazole was unable to exert its fungistatic action on a sensitive C. albicans strain in the presence of serum. The presented method can easily be integrated in the standard repertoire of a diagnostic microbiology laboratory and should prove useful as a means to assess the antifungal action of various agents on yeasts and filamentous fungi in the presence and absence of serum proteins or body fluids.Keywords
This publication has 44 references indexed in Scilit:
- In vitro Susceptibility of Fungal Isolates of Clinically Important Specimens to Itraconazole, Fluconazole and Amphotericin BChemotherapy, 1994
- Empiric amphotericin B therapy: the need for a reappraisalBlood Reviews, 1993
- Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycosesInfection, 1993
- Comparative efficacy of amphotericin B, clotrimazole and itraconazole againstAspergillus spp.Mycopathologia, 1993
- Antifungal treatment strategy in leukemia patientsAnnals of Hematology, 1992
- A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipientsMycoses, 1992
- In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agentsDiagnostic Microbiology and Infectious Disease, 1992
- Effects of Culture Media on the in vitro Susceptibility of Selected Opportunistic Fungi to Fluconazole and ItraconazoleChemotherapy, 1992
- In Vivo Interferon- Therapy Augments the In Vitro Ability of Chronic Granulomatous Disease Neutrophils to Damage Aspergillus HyphaeThe Journal of Infectious Diseases, 1991
- Amphotericin B-resistant yeast infection in severely immunocompromised patientsThe American Journal of Medicine, 1988